A recent article published in Cell presents the case of a woman with type 1 diabetes who, after receiving a transplant of reprogrammed induced pluripotent stem cells, has managed to produce her own insulin.
The operation, performed in June 2023, consisted of injecting 1.5 million pancreatic islets derived from her own stem cells from adult tissues into her abdominal muscles. This is the first time a diabetic person has been treated with her own reprogrammed adult stem cells.
The 25-year-old woman began producing enough insulin so that she did not have to receive additional doses two and a half months after the transplant. She also stopped experiencing spikes and drops in blood glucose levels.
In type 1 diabetes, which the patient suffers from, the immune system attacks the islet cells in the pancreas. In contrast, in type 2 diabetes, the body doesn’t produce enough insulin or its ability to use it decreases.
The use of the patient’s adult cells in this therapy, as described in the current publication, requires prior treatment for dedifferentiation so that they behave as induced pluripotent stem cells (iPS cells).
To achieve this, a modified version of the procedure created by Nobel Prize winner Shinya Yamanaka was used. The cells were exposed to small molecules that offered greater control over the genetic dedifferentiation process instead of introducing proteins that triggered gene expression. This gave them the ability to subsequently transform into the required cell lineage, in this case, pancreatic cells.
The woman was taking immunosuppressants for a liver transplant prior to the study, so it could not be determined whether the use of the patient’s own iPS cells reduced the risk of rejection of the graft.
The use of the patient’s own cells (autologous) generally avoids the immune rejection response, which is one of the advantages over the transplantation of cells or tissues obtained from donors (allogeneic).
Several clinical trials are currently underway in patients with both type 1 and type 2 diabetes who are receiving transplants from pluripotent stem cells and preliminary results are positive.
Gene therapy improves vision in 15 blind people
In parallel, an article published in the Lancet shows the results of a clinical trial conducted with patients suffering from Leber congenital amaurosis, a form of genetic blindness caused by biallelic mutations of the GUCY2D gene.
The study is the first to be conducted with human patients in phase 1/2 with a gene therapy to treat this disease.
Leber congenital amaurosis is a rare genetic disease of the retina characterized by degeneration of its photoreceptors, which generally causes blindness from childhood and currently has no treatment.
All patients received unilateral subretinal injections of ATSN-101, which is a recombinant adeno-associated virus serotype 5 (AAV5) vector containing the human GUCY2D cDNA under the transcriptional control of the human rhodopsin kinase (hGRK1) promoter.
Although adverse events of the treatment were described, in some cases very severe, patients improved their vision.
Bioethical assessment
The development of gene editing techniques is excellent news because of the possibility of treating pathologies for which, to date, there are no alternative cures, as in the cases mentioned above.
These techniques are being applied both to correct genetic defects and to cell reprogramming with the intention of obtaining pluripotent cells from the patient’s own adult stem cells. They are used in regenerative medicine with increasing chances of success.
The use of adult cells from patients rather than cells from embryonic tissue, which involves the destruction of human embryos, is becoming more and more common. This represents not only a technical advance in terms of efficiency, but also a major ethical advance that eliminates the use of surplus embryos from assisted reproduction techniques.
It was Nobel Prize winner Yamanaka, the discoverer of iPS cells, who motivated his research to stop using human embryos in experimentation. To this end, he created pluripotent stem cells from adult cells into which he introduced reprogramming genes that dedifferentiated them, giving them the capacity to evolve into a multitude of tissues for repair purposes.
In this, as in many other cases, the ethically acceptable solution is also the most clinically effective, leading many researchers to abandon their experiments with
in favor of using induced pluripotent stem cells (iPS) from adult tissues.
The limitations of these cells are still significant, as their genetic modification produces off-target or unintended effects that complicate their subsequent evolution. However, the possibilities of these therapies are enormous and in exponential development, which constitutes a hope for the cure of many diseases that until now were incurable.

Julio Tudela and Ester Bosch
Bioethics Observatory – Institute of Life Sciences
Catholic University of Valencia